I agree, DVEous and Robby - Avita's failure to prosper over many years is astounding. We must hold management accountable for their lack of imagination and business acumen in this regard.
As shareholders, it is of little comfort to be able to congratulate ourselves on our ability to recognise and invest in a good product when we see our share price dropping so relentlessly.
However, the fact that we CAN understand Recell's advantages suggests to me that a more comprehensive advertising campaign directed at a different marketing target - CONSUMERS - will succeed where previous efforts to attract specialists to the product have failed.
Our marketing efforts should be aimed intensively at informing health consumers and the general public about the advantages of Recell, with the aim of taking Recell out of its niche market 'backwater' and putting it fairly and squarely in the spotlight.
If CONSUMERS know about Recell, CONSUMERS will demand Recell - and DOCTORS and SPECIALISTS will have to provide it.
AVH Price at posting:
9.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)